Abstract: Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer.

Abstract: An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: CDR1: EYTIH (SEQ ID NO: 33) CDR2: NINPNX1GGTTYNQKFED (SEQ ID NO: 34) CDR3: X2-5DY (SEQ ID NO: 35) wherein X1 is N or Q, and X2-5 is YWLF (SEQ ID NO: 39), GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), and wherein if X2-5 is GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if X2-5 is YWLF (SEQ ID NO: 39), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of disease, in particular cancers, particularly prostate cancer.

Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Abstract: An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: (SEQ ID NO: 33) CDR1: EYTIH (SEQ ID NO: 34) CDR2: NINPNX1GGTTYNQKFED (SEQ ID NO: 35) CDR3: X2-5DY wherein X1 is N or Q, and X2-5 is YWLF, GWTF or AWTM, and wherein if X2-5 is GWTF or AWTM, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if X2-5 is YWLF, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer.

Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.